skip to Main Content

ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma

ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma
An update to the American Society of Clinical Oncology (ASCO) clinical practice guideline on the management of patients with potentially curative pancreatic cancer identified the combination chemotherapy regimen of 5-fluorouracil (without bolus administration), oxaliplatin, and irinotecan (modified FOLFIRINOX, also known as mFOLFIRINOX) as the preferred adjuvant therapy for patients with pancreatic adenocarcinoma who have undergone an R0 or R1 resection and have not received neoadjuvant chemotherapy.

This new recommendation was added to the previously published ASCO clinical practice guideline covering the management of these patients, and is published in the Journal of Clinical Oncology. Read more . . . . 


Back To Top